Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01, Zacks reports.

Pyxis Oncology Stock Up 0.5 %

Pyxis Oncology stock traded up $0.01 during mid-day trading on Wednesday, reaching $1.07. 81,585 shares of the company’s stock traded hands, compared to its average volume of 751,406. The company has a market cap of $63.33 million, a price-to-earnings ratio of -1.03 and a beta of 1.11. The stock has a 50 day moving average of $1.35 and a two-hundred day moving average of $2.40. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18.

Institutional Investors Weigh In On Pyxis Oncology

A hedge fund recently raised its stake in Pyxis Oncology stock. Bank of America Corp DE boosted its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,745 shares of the company’s stock after purchasing an additional 9,062 shares during the quarter. Bank of America Corp DE owned about 0.09% of Pyxis Oncology worth $84,000 as of its most recent SEC filing. 39.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on PYXS. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.